# Noninvasive Metabolic Signatures to Improve Management of Molecular Subtypes of Glioma

> **NIH NIH P01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $2,382,735

## Abstract

The overall goal of this P01 proposal is to improve the management of patients with different molecular
subgroups of glioma, focusing on novel neuroimaging surrogates associated with metabolic and physiologic
changes in each group. The delineation of histopathological and molecular subgroups of glioma has
revolutionized the field of neuro-oncology by improving diagnosis and prognosis. Interrogating metabolic and
physiologic signatures of these subgroups will be one of the next critical advances in the field of neuroimaging.
In the previous cycle of our P01, we acquired a large dataset of image-guide tissue samples matched with MR
diffusion, perfusion, and spectroscopy scans. We now seek to combine these techniques using sophisticated
data analysis tools to more efficiently predict tumor burden and malignant behavior by subgroup. Our preliminary
data also indicate that there are differences in metabolism associated with changes in IDH status and TERT
expression that have the potential for being used in developing in vivo signatures for specific molecular subtypes.
In this new proposal, we will identify multi-parametric imaging markers that are specific to each subtype; use
novel gene editing tools to elucidate mechanisms that influence the regulation of mutant TERT promotor in
subgroups with divergent molecular and clinical features; define metabolic signatures of TERT expression; and
implement novel 1H and 13C metabolic imaging strategies for monitoring individual patients during the course of
their disease. This would set the stage for developing clinical 1H and hyperpolarized 13C metabolic imaging
assays that could provide early assessment of tumor recurrence and treatment response. These integrated
studies will be supported by specialized resources from the Administrative and Clinical Services Core and the
Biospecimen and Biomarker Core. To translate our mechanistic findings and novel imaging technologies into
clinically relevant actions, we will use the unique infrastructure that our group has established over the prior
cycles of this P01 to perform studies in cells, pre-clinical models, and patients. The innovative research described
in this proposal will take advantage of the exceptional resources assembled by the well-established, collaborative
group of clinical, biological and imaging scientists at UCSF.

## Key facts

- **NIH application ID:** 10671571
- **Project number:** 5P01CA118816-15
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Susan M Chang
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $2,382,735
- **Award type:** 5
- **Project period:** 2007-07-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10671571

## Citation

> US National Institutes of Health, RePORTER application 10671571, Noninvasive Metabolic Signatures to Improve Management of Molecular Subtypes of Glioma (5P01CA118816-15). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10671571. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*